Filing Flows › Karyopharm Therapeutics (KPTI) › Q1 2026 › vs Q1 2025
Karyopharm Therapeutics (KPTI) Q1 2026 vs Q1 2025 (year over year)
Karyopharm Therapeutics's revenue rose $5.1M (+17%) from $30.0M in Q1 2025 to $35.1M in Q1 2026. The biggest changes: Product +$8.1M (+39%); License and Other −$3.1M (-34%).
Karyopharm Therapeutics, Q1 2026: revenue $35.1M (+17% year over year), operating margin -76.3%, net loss $22.4M, operating cash flow −$22.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product | $29.2M | $21.1M | $8.1M | +39% |
| License and Other | $5.9M | $9.0M | −$3.1M | -34% |
| Revenue | $35.1M | $30.0M | $5.1M | +17% |
| Other income, net | $4.4M | $9.8M | −$5.5M | -56% |
| Net loss | $22.4M | $23.5M | −$1.1M | -5% |
| Costs & expenses | $61.8M | $63.3M | −$1.5M | -2% |
| Operating costs | $61.8M | $63.3M | −$1.4M | -2% |
| Income tax | $1K | $36K | −$35K | -97% |
| Research & development | $33.8M | $34.6M | −$821K | -2% |
| SG&A | $26.7M | $27.4M | −$668K | -2% |
| Other operating costs | $1.3M | $1.3M | $44K | +3% |
| Operating cash sources | $25.7M | $42.6M | −$16.9M | -40% |
| Depreciation | $12K | $78K | −$66K | -85% |
| Share-based compensation | $3.0M | $3.6M | −$553K | -16% |
| Cash used in operations | $22.7M | $39.0M | −$16.3M | -42% |
| Net loss absorbed | $22.4M | $23.5M | −$1.1M | -5% |
| Working capital & other | $3.4M | $19.2M | −$15.8M | -82% |
Questions
How much did Karyopharm Therapeutics's revenue grow year over year in Q1 2026?
Karyopharm Therapeutics's revenue rose $5.1M (+17%) from $30.0M in Q1 2025 to $35.1M in Q1 2026.
What drove Karyopharm Therapeutics's revenue change in Q1 2026?
Product +$8.1M (+39%); License and Other −$3.1M (-34%).